UBS AM’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
Other funds holding ANIK
CM
UBS AM's ANIK Position: Q3 2026 in Review
UBS AM opened a new position in Anika Therapeutics (ANIK) in Q3 2026: 296 shares worth $5.82K. The stake represents ﹤0.01% of the portfolio and ranks #3893 among its holdings. This is a return to the name: UBS AM previously reported a position in ANIK as recently as Q3 2022.
UBS AM first reported a position in ANIK in Q2 2014 and has held it in 25 quarters since. The position peaked at $869K in Q3 2019. 122 funds tracked by Wall St. Rank hold ANIK as of Q3 2026.
- UBS AM held 296 shares of Anika Therapeutics worth $5.82K as of Q3 2026.
- Anika Therapeutics was a new UBS AM position in Q3 2026.
- Anika Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3893 holding.
- UBS AM first reported a position in Anika Therapeutics in Q2 2014 and has held it in 25 quarters since.
- UBS AM's Anika Therapeutics position peaked at $869K in Q3 2019.
- 122 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2026.
Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.